1-6 of 6
Christopher J. O'Donnell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers

Edmund I. Graziani, Matthew Sung, Dangshe Ma, Bitha Narayanan, Kimberly Marquette, Sujiet Puthenveetil, L. Nathan Tumey, Jack Bikker, Jeffrey Casavant, Eric M. Bennett, Manoj B. Charati, Jonathon Golas, Christine Hosselet, Cynthia M. Rohde, George Hu, Magali Guffroy, Hadi Falahatpisheh, Martin Finkelstein, Tracey Clark, Frank Barletta, Lioudmila Tchistiakova, Judy Lucas, Edward Rosfjord, Frank Loganzo, Christopher J. O'Donnell, Hans-Peter Gerber, Puja Sapra
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (10): 2068–2078.
https://doi.org/10.1158/1535-7163.MCT-20-0237
Published: 02 October 2020
View articletitled, PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Open the PDF for PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers in another window
Includes: Supplementary data
Journal Articles

RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

Pavel Strop, Thomas-Toan Tran, Magdalena Dorywalska, Kathy Delaria, Russell Dushin, Oi Kwan Wong, Wei-Hsien Ho, Dahui Zhou, Aidong Wu, Eugenia Kraynov, Laura Aschenbrenner, Bora Han, Christopher J. O'Donnell, Jaume Pons, Arvind Rajpal, Dave L. Shelton, Shu-Hui Liu
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2698–2708.
https://doi.org/10.1158/1535-7163.MCT-16-0431
Published: 01 November 2016
View articletitled, RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
Open the PDF for RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models in another window
Includes: Supplementary data
Journal Articles

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

Magdalena Dorywalska, Russell Dushin, Ludivine Moine, Santiago E. Farias, Dahui Zhou, Thayalan Navaratnam, Victor Lui, Adela Hasa-Moreno, Meritxell Galindo Casas, Thomas-Toan Tran, Kathy Delaria, Shu-Hui Liu, Davide Foletti, Christopher J. O'Donnell, Jaume Pons, David L. Shelton, Arvind Rajpal, Pavel Strop
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (5): 958–970.
https://doi.org/10.1158/1535-7163.MCT-15-1004
Published: 05 May 2016
View articletitled, Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
Open the PDF for Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design in another window
Includes: Supplementary data
Journal Articles

Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature

Alberto Visintin, Kelly Knowlton, Edyta Tyminski, Chi-Iou Lin, Xiang Zheng, Kimberly Marquette, Sadhana Jain, Lioudmila Tchistiakova, Dan Li, Christopher J. O'Donnell, Andreas Maderna, Xianjun Cao, Robert Dunn, William B. Snyder, Anson K. Abraham, Mauricio Leal, Shoba Shetty, Anthony Barry, Leigh Zawel, Anthony J. Coyle, Harold F. Dvorak, Shou-Ching Jaminet
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (8): 1868–1876.
https://doi.org/10.1158/1535-7163.MCT-15-0188
Published: 05 August 2015
View articletitled, Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature
Open the PDF for Novel Anti-TM4SF1 Antibody–Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature in another window
Includes: Supplementary data
Journal Articles

Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

Frank Loganzo, Xingzhi Tan, Matthew Sung, Guixian Jin, Jeremy S. Myers, Eugene Melamud, Fang Wang, Veronica Diesl, Maximillian T. Follettie, Sylvia Musto, My-Hanh Lam, William Hu, Manoj B. Charati, Kiran Khandke, Kenny Sung Kyoo Kim, Mike Cinque, Judy Lucas, Edmund Graziani, Andreas Maderna, Christopher J. O'Donnell, Kim T. Arndt, Hans-Peter Gerber
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (4): 952–963.
https://doi.org/10.1158/1535-7163.MCT-14-0862
Published: 09 April 2015
View articletitled, Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Open the PDF for Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments in another window
Includes: Supplementary data
Journal Articles

Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells

Puja Sapra, Marc Damelin, John DiJoseph, Kimberly Marquette, Kenneth G. Geles, Jonathon Golas, Maureen Dougher, Bitha Narayanan, Andreas Giannakou, Kiran Khandke, Russell Dushin, Elana Ernstoff, Judy Lucas, Mauricio Leal, George Hu, Christopher J. O'Donnell, Lioudmila Tchistiakova, Robert T. Abraham, Hans-Peter Gerber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (1): 38–47.
https://doi.org/10.1158/1535-7163.MCT-12-0603
Published: 13 January 2013
View articletitled, Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells
Open the PDF for Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells in another window
Includes: Supplementary data